Nabriva Therapeutics News Releases http://investors.nabriva.com/ Nabriva Therapeutics News Releases en Nabriva Therapeutics to Present at the Jefferies 2019 Healthcare Conference http://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-present-jefferies-2019-healthcare DUBLIN, Ireland and KING OF PRUSSIA, Pa. , May 22, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder , Chief Executive Officer, Wed, 22 May 2019 07:00:00 -0400 Nabriva Therapeutics News Releases 8921 Nabriva Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights http://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-reports-first-quarter-2019-financial DUBLIN, Ireland , May 10, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended March 31, 2019 and Fri, 10 May 2019 07:00:00 -0400 Nabriva Therapeutics News Releases 8881 Nabriva Therapeutics to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference http://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-present-bank-america-merrill-lynch-2019 DUBLIN, Ireland and KING OF PRUSSIA, Pa. , May 08, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder , Chief Executive Officer, Wed, 08 May 2019 16:01:00 -0400 Nabriva Therapeutics News Releases 8866 Nabriva Therapeutics Announces Submission of Marketing Authorization Application for Lefamulin to Treat Community-Acquired Pneumonia in Adults by European Medicines Agency http://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-announces-submission-marketing DUBLIN, Ireland , May 08, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced that the Company’s  marketing authorization application (MAA) for both the Wed, 08 May 2019 07:00:00 -0400 Nabriva Therapeutics News Releases 8861 Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-reports-inducement-grants-under-nasdaq-0 DUBLIN, Ireland , May 01, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an Wed, 01 May 2019 16:01:00 -0400 Nabriva Therapeutics News Releases 8851 Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for Intravenous CONTEPO™ (fosfomycin) for injection http://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-receives-complete-response-letter-fda-nda Issues related to facility inspections and manufacturing deficiencies at one contract manufacturer Conference call and webcast tomorrow at 8:00 a.m. EDT DUBLIN, Ireland , April 30, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged Tue, 30 Apr 2019 20:16:00 -0400 Nabriva Therapeutics News Releases 8831 Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia (CABP) and CONTEPO™ (fosfomycin for injection) to Treat Complicated Urinary Tract Infections (cUTIs) http://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-present-data-eccmid-demonstrating-0 New data continue to support lefamulin and CONTEPO as potential first-in-class antibiotics in the United States that target the most common causative pathogens of CABP and cUTI, including multi-drug resistant (MDR) strains DUBLIN, Ireland , April 11, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Thu, 11 Apr 2019 07:00:00 -0400 Nabriva Therapeutics News Releases 8821 Nabriva Therapeutics to Present at the Needham and Company 18th Annual Healthcare Conference http://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-present-needham-and-company-18th-annual DUBLIN, Ireland and KING OF PRUSSIA, Pa. , April 02, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that Chief Executive Officer Ted Schroeder , Tue, 02 Apr 2019 07:00:00 -0400 Nabriva Therapeutics News Releases 8816 Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-reports-inducement-grants-under-nasdaq DUBLIN, Ireland , April 01, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an Mon, 01 Apr 2019 07:00:00 -0400 Nabriva Therapeutics News Releases 8801 Nabriva Therapeutics Reports 2018 Financial Results and Recent Corporate Highlights http://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-reports-2018-financial-results-and-recent - Two PDUFA dates in 2019: April 30, 2019 for CONTEPO and August 19, 2019 for Lefamulin - - Company preparing for potential commercialization of two first-in-class antibiotics,  Lefamulin (IV and Oral) and CONTEPO (IV) in the United States in 2019 - DUBLIN, Ireland , March 12, 2019 (GLOBE NEWSWIRE) Tue, 12 Mar 2019 07:00:00 -0400 Nabriva Therapeutics News Releases 8771